Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance

AIDS. 2008 Jan 11;22(2):311-3. doi: 10.1097/QAD.0b013e3282f4244f.

Abstract

Besides I47A, mutation L76V at the HIV protease gene has recently been proposed to cause lopinavir resistance. This change was present in 37 (2.7%) out of 1376 patients failing protease inhibitor containing regimens. Although 26 (70%) were on lopinavir, most had previously failed other protease inhibitors and carried multiple protease inhibitor resistance mutations. Therefore, L76V does not appear to be a primary lopinavir resistance change when the drug is used in combination therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • Codon / genetics
  • Drug Resistance, Multiple, Viral / genetics
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV Protease / drug effects
  • HIV Protease / genetics*
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / drug effects*
  • Humans
  • Lopinavir
  • Point Mutation
  • Pyrimidinones / pharmacology*
  • Spain

Substances

  • Codon
  • HIV Protease Inhibitors
  • Pyrimidinones
  • Lopinavir
  • HIV Protease